Lung Cancer | Tumor

Despite Rapid Increase in Immunotherapy Use for Lung Cancer, Survival Benefit for Older Patients Is Modest

February 2nd 2023

Since 2015, the use of immunotherapies has increased for both young and older patients, but the survival benefit is more evident in younger patients, findings demonstrated.

Trial to Investigate If Novel Drug Combo Can Boost Outcomes in Lung Cancer

January 31st 2023

A phase 3 trial will test datopotamab deruxtecan in combination with Keytruda with or without chemotherapy for certain patients with metastatic non-small cell lung cancer.

Trial to Investigate Novel Drug in KRAS-Mutant Lung Cancer

January 27th 2023

VIC-1911 will be studied alone or with Lumakras in patients with KRAS G12C-mutant non-small cell lung cancer.

FDA Approves Post-Surgical Keytruda for Lung Cancer Subset

January 26th 2023

The Food and Drug Administration approved Keytruda, an immunotherapy agent, for patients with stage 1B, 2 or 3A non-small cell lung cancer.

Iadademstat-Placebo Combo to Be Studied in Neuroendocrine Cancers

January 26th 2023

Researchers just launched a phase 2 trial evaluating iadademstat plus paclitaxel in patients with relapsed/refractory neuroendocrine cancer, including those with small cell lung cancer.

Immunotherapy Plus Chemo Boosts Event-Free Survival in Resectable Lung Cancer

January 18th 2023

Patients with operable non-small cell lung cancer who were treated with an anti-PD-1 monoclonal antibody plus a doublet chemotherapy regiment did not experience cancer recurrence or new symptom onset during follow-up in a recent study.

New KRAS Inhibitor to Be Studied in Lung, Colon and Pancreatic Cancers

January 18th 2023

The COVALENT-102 trial will investigate BMF-219 in patients with non-small cell lung cancer, colorectal and pancreatic cancers.

Creating an Advocacy Group at the Onset of a Global Pandemic: KRAS Kickers Founder Shares Her Story

December 29th 2022

Lung cancer survivor Terri Conneran shares her story of creating a non-profit to help connect with fellow patients and survivors who have the KRAS biomarker.

FDA’s Approval of Krazati Demonstrates ‘Watershed Moment’ for Treatment of NSCLC With Genetic Mutation

December 21st 2022

An expert explains what the FDA’s accelerated approval of Krazati means for patients with KRAS G12C-mutant locally advanced or metastatic non-small cell lung cancer and what he hopes will come next.

FDA Expands Indication for Pemfexy to Include Subset of Advanced Non-Small Cell Lung Cancer

December 19th 2022

The indication for Pemfexy has been approved to include patients with metastatic, non-squamous, non-small cell lung cancer without EGFR or ALK genomic tumor mutations.

20 Years of Cancer Care Advancements

December 15th 2022

In honor of CURE®’s 20th anniversary, here is a roundup of some of the major advancements in the world of cancer care, according to experts, patients and advocates.

FDA Approves Krazati for KRAS G12C-Mutant Lung Cancer

December 13th 2022

Krazati was granted an accelerated approval for patients with KRAS G12C-mutant locally advanced or metastatic non-small cell lung cancer, according to the Food and Drug Administration.

Evaluating Existing and Future Surgical Options for Early-Stage Lung Cancer

November 23rd 2022

As part of its “Speaking Out” video series, Dr. Peter Baik, on behalf of Cancer Treatment Centers of America, discussed how far the space has come with surgical advances, and where it is headed, in treating early-stage lung cancer.

‘Time is of the Essence’ in Decision-Making for Early-Stage Lung Cancer

November 23rd 2022

As part of its “Speaking Out” video series, Dr. Peter Baik, on behalf of Cancer Treatment Centers of America, discussed the importance of timing and decision-making of treatment in early-stage lung cancer.

Expert Addresses Disparities in Lung Cancer Screening, What More Can Be Done

November 23rd 2022

As part of its “Speaking Out” video series, Dr. Peter Baik, on behalf of Cancer Treatment Centers of America, discussed disparities seen in lung cancer screening and what more can be done.

Libtayo’s Approval Part of the ‘Renaissance’ of Lung Cancer Advancements

November 18th 2022

The recent FDA approval of Libtayo for advanced non-small cell lung cancer added yet another option for the treatment of patients with the disease.

‘Star Trek’ Actors Team Up for Cancer Research, Michelle Obama Meets a Sarcoma Survivor and More

November 18th 2022

From “Star Trek” actors supporting the Pancreatic Cancer Action Network to Michelle Obama meeting with a sarcoma survivor and an update on Jane Fonda’s cancer, here’s what’s happening in the cancer space this week.

A Glimmer of Hope for Those With Lung Cancer

November 16th 2022

Screening After a Lung Cancer Diagnosis

November 15th 2022

Does lung cancer screening continue after a person is finished with treatment and moves in to the survivorship stage?

Biomarker Testing Provides 'Real Potential' to Manage Lung Cancer

November 14th 2022

Identifying genetic mutations in lung cancer has allowed researchers to develop treatments that target specific biomarkers over the past 20 years, but more research is needed to further the space.

'Considerable Overlap’ in Appearance of Chest Abnormalities May Delay Lung Cancer Diagnoses

November 14th 2022

Patients should describe their symptoms in detail and seek early care for suspected lung cancer, especially since the disease may resemble pneumonia and bronchitis on imaging tests.

Improving Breathing After Lobectomy

November 11th 2022

Light exercises, which can be done at home, may be beneficial for patients with lung cancer.

FDA Approves Imjudo With Imfinzi and Chemo for Metastatic NSCLC Without Certain Genetic Mutations

November 10th 2022

Imjudo, Imfinzi and chemotherapy improved overall and progression-free survival in certain patients with non-small cell lung cancer.

Targeting the 'Typos' for Lung Cancer Harboring Rare Genetic Mutations

November 9th 2022

New treatments may stall lung cancer progression in patients with EGFR exon 20 insertion mutations.

FDA Approves Libtayo Plus Chemotherapy for Advanced Lung Cancer Subset

November 9th 2022

The Food and Drug Administration approved Libtayo plus chemotherapy for certain patients with non-small cell lung cancer.

Detecting Lung Cancer on the Move

November 8th 2022

Tumors can spread from one lung to the other and beyond. How are possible cancer metastases diagnosed in early stages?

Providing Hope to Patients With Cancer Is the Best Part of the Job, Says an Oncologist

November 7th 2022

With advancements making a “huge difference” in lung cancer outcomes, one surgical oncologist said that offering his patients hope is the best part of his job.

Clinical Trial Kicks Off Evaluating a New Drug for a Group of Solid Cancers

November 4th 2022

A novel drug, MRT-2359, will be studied in a phase 1/2 trial for patients with MYC-driven cancers.

End-of-Life Discussions Can ‘Lay Out a Roadmap’ of Patient Wishes and Avoid Unnecessary Cancer Care

November 2nd 2022

Talking about the end of life can be difficult, but these conversations are crucial for patients with incurable cancer to have with their clinicians, experts say.

A Lung Cancer Diagnosis Inspired a Research Nurse to Fight Stigma Around the Disease

October 31st 2022

After receiving a life-changing lung cancer diagnosis, Alesha Arnold was inspired to give back to her community and improve the lives of patients with the disease.